CRISPR Therapeutics Moves Into Off-The-Shelf CAR-T Lead, But Durability Test Awaits
Allogene Remains A Rival Despite Safety Hiatus
Some remain unconvinced on durability, but CRISPR Therapeutics is looking at a second ‘consolidation’ dose and other measures to boost CTX110’s efficacy in a pivotal trial.
You may also be interested in...
Allogene is the frontrunner in the allogeneic CAR-T field but must assess whether or not its therapy could have caused a patient’s unexpected chromosomal abnormality.
As rival Phase III gene therapy trials get underway, Sarepta’s product could have the edge in safety and efficacy over its rival from Pfizer, but the chance of failure remains high.
Company follows US office downsizing with similar plans for its global headquarters, once consumer health spin-out is complete in 2022.